Uremide

Quick links to important sections

Uremide

Selected form

Method of action: Antihypertensive, Diuretic

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Uremide

Property Description
Active ingredient Furosemide
Form Tablets, Oral Solution, Injection (Ampoules)
Pharmacological class High-Ceiling Diuretic (Loop Diuretic)
General purpose Relieving fluid overload (edema)
Origin Synthetic drug (Sulfonamide derivative)

Uremide is a powerful prescription-only medicine (Rx only) whose active ingredient is Furosemide, primarily used to manage fluid balance in the body. It is clinically recognized for its rapid onset of action and high efficacy in situations demanding prompt fluid removal.


What Type of Medicine is Uremide and Its Composition?

Uremide belongs to the pharmacological class known as Loop Diuretics, due to its mechanism in the kidney's loop of Henle. The medicine's core component is the synthetic substance Furosemide, which is chemically defined as a sulfonamide derivative.

Furosemide is indicated as a Loop Diuretic with a chemical structure related to anthranilic acid. It is categorized as an essential medicine, a designation for drugs critical for a functioning health system.


Furosemide: The General Purpose of a Loop Diuretic

The general purpose of Furosemide is to induce diuresis, a significant increase in the production and excretion of urine, by facilitating potent natriuresis (salt removal). This action rapidly helps relieve the body of fluid overload and accumulated swelling (edema). A typical use scenario involves managing acute fluid retention, providing rapid relief from swelling. By aggressively preventing the kidney from reabsorbing sodium and water, the drug successfully reduces overall fluid volume and lessens the burden on the cardiovascular system.


Available Forms of Uremide (Tablets and Injection)

Uremide is available in multiple pharmaceutical preparations to suit different patient needs, including tablets for oral use and a parenteral formulation known as an injection packaged in ampoules. These variations ensure that Furosemide can be administered either for routine, maintenance fluid management or rapidly via intravenous or intramuscular routes when immediate, powerful action is required. Uremide is a single-component medication, containing only the active ingredient Furosemide.

Regulatory References

  1. WHO Essential Medicines List entry for Furosemide

What side effects are possible with Uremide?

Possible side effects and safety information

The official safety profile for Uremide (Furosemide) is characterized by adverse reactions classified across multiple organ systems and based on incidence rates defined in regulatory documents.

Frequency-Classified Adverse Reactions

The most frequent adverse events are directly related to the medicine's primary action. Regulatory documents classify Very Common events as those concerning fluid, electrolyte, and metabolic disturbances, including dehydration, hypovolemia, and imbalances of potassium and sodium.

Effects classified as Common include orthostatic hypotension and elevated levels of blood glucose (hyperglycemia) and uric acid (hyperuricemia).

Uncommon reactions include thrombocytopenia (low platelet count), photosensitivity, and certain visual disturbances.

Systemic Reactions and Safety Constraints

Adverse reactions across System-Organ Classes include effects on the blood and lymphatic system (e.g., aplastic anemia, agranulocytosis), skin and subcutaneous tissue (e.g., Toxic Epidermal Necrolysis), and ear and labyrinth disorders (e.g., deafness and tinnitus).

Serious adverse reactions officially documented include life-threatening skin conditions (Stevens-Johnson Syndrome), severe allergic (anaphylactic) reactions, and potentially irreversible hearing loss.

Safety notes specify that elderly patients carry a heightened risk of dehydration and subsequent thrombosis/embolism. The medicine is contraindicated in conditions such as anuria and pre-existing hepatic coma. Furthermore, the risk of ototoxicity is noted to increase when the medicine is delivered by rapid intravenous injection.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Uremide (Furosemide) is characterized by an excessive extension of its potent diuretic action. This results in profound diuresis leading to severe dehydration and significant blood volume reduction (hypovolemia).

Documented Manifestations

Clinical signs and symptoms related to fluid and electrolyte depletion may include hypotension (low blood pressure), excessive thirst, weakness, muscle cramps, lethargy, and arrhythmia (irregular heartbeat). Laboratory findings typically involve severe imbalances such as hypokalemia, hyponatremia, and hypochloremic alkalosis.

Severe Outcomes and Action Mandates

Severe consequences can include circulatory collapse, vascular thrombosis, and embolism, with elderly patients being at increased risk for vascular events. Patients with hepatic cirrhosis face the risk of precipitating hepatic encephalopathy or coma.

Urgent medical attention is required for any suspected overdose or the onset of severe symptoms. Treatment is officially defined as supportive, consisting of the mandatory replacement of excessive fluid and electrolyte losses. No specific antidote is known for Furosemide, and frequent monitoring of serum electrolytes and blood pressure is required during management.

Therapeutic Uses of Uremide

Uremide is a medication generally considered relevant for supportive symptom management across therapeutic areas where patients experience fluid retention and associated systemic imbalance. It is commonly used to address the symptomatic edema (excess fluid) caused by various conditions, including congestive heart failure, cirrhosis of the liver, and specific forms of renal disease, providing a means of easing symptoms related to excess fluid.

Uremide plays a role in managing symptoms related to volume overload. It is frequently applied in both chronic care to manage persistent swelling and in acute clinical settings, such as sudden fluid escalation or hypertensive episodes, where short-term symptomatic assistance is needed. This therapeutic approach supports patients by easing the physical discomfort of peripheral swelling and may assist with maintaining a sense of stability when symptoms are more noticeable. It helps ease symptoms linked to organ-specific functional stress.

Quick Fact: Relief for Fluid Retention Symptoms Uremide is used for managing symptoms related to systemic imbalance, which includes swelling in the extremities and pulmonary congestion, helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Uremide?

Uremide (Furosemide) eligibility is defined by regulatory bodies based on a patient’s physiological status, existing medical conditions, and life stage. The medicine is approved for use in adults and pediatric patients for all labeled indications, such as edema associated with heart failure or renal disease.

Populations Who Must Not Use Uremide

Use is contraindicated in individuals with anuria (the inability to produce urine) or a known hypersensitivity to furosemide. It is also prohibited in states of severe electrolyte imbalance, such as severe hypovolemia (low blood volume) or severe hypokalaemia, and in patients with hepatic encephalopathy (hepatic coma). Some regulatory authorities state that use is contraindicated during breastfeeding.

Conditional and Restricted Use

Special monitoring is required for patients with severe progressive renal disease or hepatic cirrhosis and ascites. Use is restricted in patients with severe urinary retention symptoms to ensure adequate flow. Older adults require cautious use due to an increased risk of dehydration. Premature infants are an eligible population but require specific monitoring for potential kidney complications. Use during pregnancy is conditional and generally not recommended unless compelling medical reasons exist.

What should I know about interactions with other medicines?

Uremide, whose active ingredient is Furosemide, has officially documented interaction patterns primarily concerning organ toxicity, blood pressure, and drug clearance.

Contraindicated Combinations and Organ Toxicity

Specific combinations are restricted due to severe risk. Furosemide should generally be avoided with aminoglycoside antibiotics and ethacrynic acid, as co-administration greatly increases the potential for ototoxicity (hearing damage) and nephrotoxicity (kidney damage). The risk of ototoxicity is noted to be potentiated in patients with severe renal impairment or hypoproteinemia.

Pharmacodynamic and Clearance Interactions

Category Interacting Agents (Examples) Regulatory-Described Outcome
Altered Clearance Lithium Furosemide reduces the renal clearance of Lithium, raising the risk of toxicity from increased plasma levels.
Additive Effects ACE Inhibitors / ARBs Potentiation of effects, leading to the risk of severe hypotension and deterioration in renal function.
Reduced Efficacy Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Reduced diuretic effect of Furosemide and increased risk of acute renal failure.
Electrolyte Loss Corticosteroids, Liquorice Increased risk of hypokalemia (low potassium).

Timing and Absorption Rules

To prevent the reduction of Furosemide's absorption and effect, regulatory documentation requires that sucralfate must be administered at least 2 hours before or after Furosemide. Additionally, Phenytoin reduces the diuretic effect via a pharmacokinetic interaction involving increased non-renal clearance.

Mechanism of Action

Mechanism of Action

Uremide exerts its primary effect through Renal Electrolyte Transport Inhibition. The drug acts as an inhibitor by binding to the Na^+- K^+- 2Cl^- cotransporter (NKCC2), which is primarily located in the thick ascending limb of the loop of Henle in the kidney. This molecular interaction blocks the reabsorption of sodium ( Na^+), potassium ( K^+), and chloride ( Cl^-) ions from the forming urine back into the bloodstream.

This inhibition results in Fluid and Volume Modulation. The high concentration of salt retained within the kidney's fluid creates an osmotic gradient that drives water loss. This cascade increases the urinary excretion of water and electrolytes, leading to a reduction in total circulating blood volume and extravascular fluid.

Simultaneously, Uremide contributes to the Modulation of Peripheral Vascular Tone through a direct action that facilitates the relaxation of vascular smooth muscle in certain peripheral blood vessels. The combination of reduced volume and lowered vascular resistance results in a net decrease in pressure within the circulatory system, defining the drug's physiological effect profile.

Dosage and Administration Information

How to Use Uremide

Uremide (Furosemide) administration is characterized by specific parameters outlining the appropriate route, dosing schedule, and conditions for intake.


Administration Routes and Dosing Principles

The medication is administered via oral intake (tablets and solution) for routine and maintenance fluid management, or as a parenteral solution for urgent, acute clinical needs via intravenous (IV) or intramuscularly (IM) routes. A specialized subcutaneous (SC) route is also used for specific adult chronic conditions.

The dosing schedule for adults managing edema typically initiates with a low starting dose between 20 mg and 80 mg taken once daily. This dose is then titrated (gradually adjusted) based on the required response, within specified maximum limits. Initial IV/IM doses are generally 20 mg to 40 mg. Pediatric dosing is determined by body weight, and older adults are typically started on a lower initial dosage.


Frequency and Special Conditions

The use pattern involves administration once or twice daily, or sometimes utilizing an intermittent schedule (e.g., alternate days) for long-term maintenance. Oral forms may be taken with or without food. Specific administration constraints apply to the injectable solution: it is administered slowly over 1 to 2 minutes, with the maximum controlled intravenous infusion rate not exceeding 4 mg/min in adults. This procedural constraint ensures the proper delivery of the medicine in a supervised setting.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Uremide

This overview summarizes the formal clinical research that has evaluated Uremide (Furosemide) for managing fluid retention, focusing on the study designs, the outcomes that were measured, and what scientific evidence reports, without giving clinical advice.


Evidence for Fluid Overload (Edema) in Heart Failure

The majority of research exploring Uremide in this area involves adult populations with heart conditions that cause fluid retention. The evidence base consists of both long-term and short-term Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses.

Studies focused on measuring changes in fluid balance, such as weight change and urine production. Research has explored this core purpose extensively, but data are still emerging regarding findings on mortality when compared to alternative diuretic agents. Long-term effects and outcomes are not fully established across all possible patient profiles.

Evidence for Fluid Retention in Chronic Kidney Disease

Research has explored Uremide's use in adults with impaired kidney function who experience fluid retention. Studies monitored physiological strain by measuring urine volume, the amount of salt excreted (natriuresis), and by tracking standard kidney function biomarkers.

Research highlights changes measured in fluid output and salt excretion. Evidence quality varies across studies, and there is limited information for long-term outcomes regarding whether Uremide specifically influences the progression of the underlying chronic kidney condition over many years.

Evidence for Managing Fluid Retention (Ascites) in Cirrhosis

Uremide was evaluated in studies involving adults with liver cirrhosis and ascites (fluid accumulation in the abdomen). Research often involves comparative trials examining Uremide as part of a combination regimen with another class of diuretic.

Findings describe patterns observed in the combination therapy setting related to fluid removal and measured weight loss. However, research into using Uremide as monotherapy (used alone) for ascites management is generally considered insufficient, as the standard clinical approach emphasizes the combination strategy.

Research Gaps and Areas of Uncertainty

The broader evidence landscape highlights areas where research is ongoing or where certainty remains low. A key limitation is that many contemporary trials compare Uremide against newer diuretics rather than a true non-treatment control, meaning comparative evidence is lacking for some long-term benefits versus no diuretic. Data for certain specific patient groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Uremide (FAQ)


Q: What is the main reason Uremide is prescribed?

A: The primary reason Uremide is prescribed is to manage fluid retention, or edema, in the body. Official regulatory documents indicate its use is related to fluid buildup caused by chronic conditions like kidney disease, liver disease, or congestive heart failure.


Q: How quickly should I expect Uremide to start working?

A: According to the official product information, the initial effect of the oral form of Uremide typically begins within one hour of administration. The greatest effect (peak action) is generally observed during the first 1 to 2 hours following the dose.


Q: How long does Uremide stay in your system?

A: Regulatory information describes the duration of action for Uremide as lasting approximately 6 to 8 hours after an oral dose. This timeframe refers to how long the intended effect is typically observed in the body.


Q: Can Uremide be taken with common pain relievers like ibuprofen?

A: Regulatory documents describe a known interaction between Uremide and non-steroidal anti-inflammatory drugs (NSAIDs), which include common pain relievers like ibuprofen. This information is included within the official section on drug interactions.


Q: Is it okay to drink alcohol while taking Uremide?

A: Official product information notes that Uremide has the potential to cause dizziness and low blood pressure (hypotension). These effects are described as potentially being increased by the use of alcohol.


Q: What are the most commonly reported side effects of Uremide?

A: Regulatory documents list adverse reactions, including increased urination (diuresis), dizziness, low blood pressure (hypotension), and changes in body electrolytes, such as reduced potassium levels (hypokalemia).


Q: Does Uremide cause weight gain or weight loss?

A: Uremide’s function is to help the body excrete excess fluid, which is the definition of diuresis. This intended effect can lead to a reduction in fluid weight, and subsequent changes in body weight are described as a related outcome of the drug’s use.


Q: Can Uremide affect my sleep patterns?

A: Official regulatory sources list certain effects on the central nervous system (CNS) as possible adverse reactions. These sometimes include restlessness, which may indirectly relate to sleep patterns.


Q: Is Uremide a long-term medication, or is it only for short use?

A: Official prescribing information indicates that Uremide is approved for managing fluid retention (edema) under various usage patterns. This includes both short-term use and daily or intermittent schedules required for long-term maintenance of the condition.


Q: Is Uremide safe for elderly people?

A: Official documents specifically address the use of Uremide in older adults. Regulatory information indicates that it may be used in this population, and the prescribing principles for this group often specify starting with a lower initial dose.


Q: Can women who are pregnant or breastfeeding use Uremide?

A: Regulatory sources provide specific safety risk summaries related to use during pregnancy (classified as Category C) and lactation. Official product information notes that the drug is excreted into human milk.


Q: Are there any specific foods or drinks to avoid when taking Uremide?

A: Because of Uremide’s effect on sodium and potassium levels in the body (electrolytes), official sources may advise on the need for specific dietary instructions. These instructions relate primarily to the management of sodium and potassium intake.


Q: Does Uremide interact with supplements like potassium or magnesium?

A: Official documents describe the potential for Uremide to interact with or alter the levels of certain electrolytes. This includes changes to the levels of potassium and magnesium in the body.


Q: Can Uremide cause dry mouth or changes in taste?

A: Official regulatory adverse reaction lists include dry mouth as a possible effect. Additionally, changes in taste sensation, medically termed dysgeusia, are also noted as a potential reaction.


Q: Are there any known interactions between Uremide and birth control pills?

A: Regulatory information includes described interactions with oral contraceptives (birth control pills). These interactions specifically relate to how the drug might affect hormone levels in the body.


Q: Does Uremide affect blood sugar levels?

A: Official regulatory documents list hyperglycemia as a possible metabolic adverse reaction. Hyperglycemia is the medical term used to describe an increase in blood sugar levels.


Q: What does the official research say about the long-term use of Uremide?

A: Official regulatory documents contain summaries of the clinical studies that provided evidence for the drug’s approval. These summaries provide data related to both the effectiveness and safety of Uremide over the course of use.


Q: Why do official documents mention Uremide having a 'Boxed Warning'?

A: The U.S. FDA label includes a Boxed Warning to highlight the risk of profound diuresis. This refers to excessive fluid loss which could potentially lead to dehydration and depletion of electrolytes in the body.


Q: What conditions make someone ineligible to use Uremide?

A: Regulatory documents list specific contraindications, which are conditions that make someone ineligible for use. Examples include a complete inability to urinate (anuria) or a known history of hypersensitivity (allergic reaction) to Uremide.


Q: Do children or teenagers ever use Uremide?

A: Official regulatory documents include information addressing the use of Uremide in the pediatric population (children and teenagers). For this group, the information indicates that dosing is determined based on body weight.


Q: Is it normal to feel tired or dizzy when first starting Uremide?

A: Dizziness and asthenia, which refers to weakness or lack of energy, are commonly reported effects. Both are listed among the possible adverse reactions in official regulatory documents.


Q: Can Uremide be split in half if the tablet is scored?

A: Regulatory information describes the available dosage forms, including the tablets. This information typically specifies whether the tablets are scored and contains information regarding how the tablet may be divided.


Q: Are there any known drug-drug interactions with common antidepressants?

A: Official regulatory documents list specific classes of medications that may have described interactions with Uremide. These classes include certain types of commonly used antidepressants.


Q: Does Uremide interact with herbal remedies like St. John’s Wort?

A: Official regulatory sources include general warnings regarding potential interactions with herbal products. This guidance addresses the possibility that herbal remedies, such as St. John’s Wort, may affect the drug’s efficacy or metabolism.


Q: Is Uremide available over the counter, or is it prescription-only?

A: Regulatory information from official sources confirms that Uremide is classified as a prescription-only medicine. It is not available for purchase over the counter.


Q: What are the expected benefits of Uremide in patient studies?

A: Regulatory documents summarize the results of clinical trials that led to the drug’s approval. These summaries provide information on the primary outcomes and the intended benefits that were demonstrated in the patient studies.


Q: Do I need to change my diet while taking Uremide?

A: Official regulatory documents advise that specific dietary instructions may be needed while taking Uremide. This is due to the drug’s effects on key electrolytes, particularly the levels of sodium and potassium.


Q: Is Uremide known to affect kidney function over time?

A: Changes in markers of kidney function are listed as possible adverse reactions in regulatory documents. These markers include elevated blood urea nitrogen (BUN) or creatinine levels.


Q: Are there different forms or strengths of Uremide available?

A: Regulatory documents explicitly list all available dosage forms. These commonly include oral tablets and oral solutions, along with the specific strengths in which they are supplied.


Q: Why is Uremide often taken in the morning?

A: Patient information guides often suggest administering the drug in the morning. This schedule is generally recommended to help manage the intended effect of increased urination (diuresis) and minimize the disruption it may cause to sleep.


Q: Does Uremide cause headaches or migraines?

A: Headaches are included among the possible adverse reactions reported in official regulatory documents.


Q: Can Uremide cause an allergic reaction?

A: Official regulatory sources list hypersensitivity, or allergic reactions, as both an important adverse reaction and a condition that contraindicates the use of the medication.


Q: What types of heart conditions make Uremide use complicated?

A: While the drug is indicated for conditions like congestive heart failure, official documents describe precautions related to cardiac function. Specific contraindications and warnings regarding severe heart issues are detailed in the product information.


Q: Are there any required lab tests before starting Uremide?

A: Regulatory documents specify the requirement for routine monitoring when using Uremide. This monitoring involves specific lab tests for parameters such as electrolytes and kidney function markers.


Q: Does Uremide affect my ability to drive or operate machinery?

A: Regulatory information explicitly includes a warning regarding the potential for dizziness and low blood pressure (hypotension), which could affect a person's ability to drive or operate machinery.


Q: Why is Uremide contraindicated for people with certain electrolyte imbalances?

A: The drug's mechanism involves acting directly on key electrolytes, such as sodium and potassium. Official product information states that certain pre-existing electrolyte imbalances are a specific contraindication for the use of Uremide.


Q: Does Uremide interact with common blood thinners like warfarin?

A: Regulatory documents describe potential interactions between Uremide and anti-coagulants, which include common blood thinners like warfarin. Official guidance often indicates the need for monitoring during co-administration.


Q: What is the typical timeframe for seeing the full effect of Uremide?

A: Regulatory documents provide information on the timeframe for the peak effect of the drug. For example, peak diuresis (maximum fluid excretion) is typically described as occurring within 1 to 2 hours.


Q: What kind of monitoring is typically involved when taking Uremide?

A: Official regulatory documents specify that routine monitoring is required while taking Uremide. This includes monitoring of fluid status, electrolyte levels, and kidney function markers.


Q: What are the official safety classifications for Uremide?

A: Official documents provide specific regulatory classification information for the drug. This includes the pregnancy category and other details related to warnings and precautions for use in specific populations.


Q: How does Uremide's purpose relate to hypertension?

A: Regulatory documents confirm that Uremide is approved for managing fluid retention that may be associated with high blood pressure (hypertension). It is also described as a treatment that may be used, alone or with other drugs, to help manage hypertension.


Q: Is Uremide a generic drug or a brand name?

A: Official regulatory documents name the generic substance, Furosemide, as well as the related brand names. This clarifies its classification as a drug available in generic form.


Q: Does Uremide need to be stored at a specific temperature?

A: Regulatory information provides explicit instructions for the proper storage of the drug. These instructions detail the required temperature ranges and specific conditions to maintain product integrity.


Q: What evidence supports the use of Uremide in certain patient populations?

A: Clinical study summaries contained in regulatory documents provide the evidence that supports the use of the drug. This includes details from trials involving specific age groups or conditions.


Q: How does Uremide affect blood pressure, generally speaking?

A: Regulatory information indicates that Uremide is approved for use in conditions where a reduction in fluid volume is necessary. This reduction in fluid can generally affect high blood pressure.

How should Uremide be stored and disposed of?

How to Store and Dispose of Uremide

Official Storage Requirements

Uremide must be stored at Controlled Room Temperature, generally defined as 20 C to 25 C, with short excursions permitted up to 30 C. The medication must be kept in the original, tightly closed container and protected from light and moisture. Regulatory labeling advises against storing Uremide in damp, high-heat locations like the bathroom or a car, as these conditions may compromise stability. Furosemide Oral Solution has an explicit in-use stability limit and should be discarded 90 days after opening.

Disposal and Child Safety

It is mandatory that Uremide be stored out of the sight and reach of children. For disposal, unused or expired product should be returned to a pharmacy or official drug take-back program. Regulatory guidance instructs users not to flush this medication down the toilet; if a take-back program is unavailable, the drug should be mixed with an unappealing substance and placed in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Uremide found in:

A-Z Index: